Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Astera Labs filings document a Nasdaq-listed semiconductor connectivity company serving rack-scale AI infrastructure. The company’s Form 8-K reports cover quarterly and annual operating results, product and demand commentary tied to PCIe 6, Scorpio smart fabric switches, signal conditioning and Smart Cable Modules, and material business updates.
ALAB regulatory disclosures also record its common stock listing on the Nasdaq Global Select Market, emerging growth company status, executive officer appointments and compensation arrangements, and material definitive agreements, including customer-linked warrant terms. Proxy materials describe annual meeting proposals, board elections, auditor ratification, executive compensation votes and stockholder voting mechanics.
BlackRock, Inc. reports beneficial ownership of 12,667,232 shares of Astera Labs Inc. common stock, representing 7.4% of the outstanding class as of June 30, 2026. BlackRock has sole voting power over 11,998,990 shares and sole dispositive power over all 12,667,232 shares.
The position is held across certain reporting business units of BlackRock and its subsidiaries. Various underlying clients have rights to dividends and sale proceeds, but no single client has more than 5% of Astera Labs’ total outstanding common shares.
Cota Germaine reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. granted Chief Accounting Officer and VP, Finance Germaine Cota an award of 1,451 restricted stock units of common stock on July 20, 2026 under its 2024 Stock Option and Incentive Plan. Following this award, Cota directly holds 26,440 shares of common stock.
The award provides that 6.25% of the RSUs shall vest in 16 equal quarterly installments after the vesting commencement date of August 15, 2026, conditioned on a continuous service relationship with the company. Each RSU represents a contingent right to receive one share of common stock.
Astera Labs director Manuel Alba reported pre-planned insider sales tied to an affiliated entity. On July 1, 2026, Casa Alameda 2007, LLC, of which Alba is a manager, sold 8,491 shares of Astera Labs common stock in multiple open-market transactions under a Rule 10b5-1 trading plan adopted on May 29, 2025.
The Form 4 notes weighted average sale prices, with individual trades executed in ranges from $451.4600 to $468.0000 per share. After these transactions, Casa Alameda 2007, LLC held 286,863 shares indirectly, while Alba also reported 2,351 shares held directly and 5,000 shares held indirectly by his spouse. Alba disclaims beneficial ownership of the LLC-held shares except to the extent of any pecuniary interest.
Astera Labs, Inc. director Manuel Alba reported a series of automatic, pre-planned stock sales linked to entities associated with him. On July 1, 2026, Casa Alameda 2007, LLC and the Alba 2003 Living Trust together sold 37,535 shares of Astera Labs common stock in 29 open-market transactions.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025. Alba disclaims beneficial ownership of the securities held by Casa Alameda 2007, LLC and by the Alba Trust, except to the extent of any pecuniary interest.
Astera Labs director-related trust reports pre-planned stock sales. Alba 2003 Living Trust, associated with director Manuel Alba, sold a total of 136,974 shares of Astera Labs common stock on July 1, 2026 in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The reported sale prices ranged from $429.11 to $459.44 per share, based on weighted-average pricing disclosures. Following these transactions, the trust continues to hold 1,287,524 shares of Astera Labs common stock indirectly for the benefit of the Alba 2003 Living Trust, with Manuel Alba-Marquez and his spouse as co-trustees, and Manuel Alba disclaiming beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported planned stock sales through various entities. On 2026-07-01, entities associated with him sold a total of 12,499 shares of Astera Labs common stock at $450.00 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The sales included 3,505 shares from his direct holdings, 8,333 shares held by a trust, and 661 shares held by a limited partnership. After these transactions, reported positions include 57,466 shares held directly, 311,399 shares held by a trust, 4,631 shares held by a limited partnership, and several smaller indirect holdings, with Dyckerhoff disclaiming beneficial ownership except for his pecuniary interests.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting an intended sale of 170,000 shares of Common Stock of ALAB. The filing lists an associated figure of $82,113,400.00 and shows 171,407,939 shares outstanding as of 07/01/2026. The securities were acquired 03/21/2018 in a Private Acquisition from Issuer or an Affiliate for Cash.
ALAB notice of proposed sale of 33,000 shares of Common Stock through broker Morgan Stanley Smith Barney LLC. The shares were acquired 11/30/2018 in a Private Acquisition from Issuer or an Affiliate and are listed with a value of $15,939,660.00. The form references NASDAQ and a date of 07/01/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice to sell 150,000 shares of Common Stock of ALAB listed on NASDAQ. The shares were acquired privately on 03/21/2018 and the proposed sale method is listed as cash. The excerpt shows an associated aggregate figure of $72,453,000 and 171,407,939 shares outstanding as of 07/01/2026.
ALAB reported proposed and recent sales of Common stock in a Form 144 notice, listing securities to be sold and multiple transactions by a named holder. The filing lists selling-party transactions and earlier private placement distributions from Sutter Hill Ventures A CA LP.
Examples in the filing show recent sales by Stefan Dyckerhoff: 11,599 shares on 04/17/2026 for $2,029,828.00, 13,399 shares on 04/20/2026 for $2,346,435.00, 12,499 shares on 05/07/2026 for $2,500,174.00, and 12,499 shares on 06/03/2026 for $4,553,995.00. The filing also records prior private placement receipts and pro‑rata distributions dated 02/07/2020 through 05/17/2022 from Sutter Hill Ventures A CA LP.